Copyright
©The Author(s) 2018.
World J Hepatol. Jan 27, 2018; 10(1): 51-61
Published online Jan 27, 2018. doi: 10.4254/wjh.v10.i1.51
Published online Jan 27, 2018. doi: 10.4254/wjh.v10.i1.51
Table 1 Treatment modalities and the stage of the disease in patients with hepatocellular carcinoma
| Treatment modality | Pts within expanded criteria, n (%) | Pts within Milan criteria, n (%) | Total, n | BCLC stage | Survival, n (%) | |||
| 0-A | B | C | D | |||||
| Surgical resection | 24 (89) | 19 (70) | 27 | 18 | 9 | 0 | 0 | 16 (59) |
| OLT | 47 (84) | 41 (73) | 56 | 24 | 13 | 7 | 12 | 56 (100) |
| Percutaneous ablation | 16 (94) | 15 (88) | 17 | 11 | 1 | 3 | 2 | 10 (59) |
| TACE | 118 (69) | 99 (58) | 172 | 81 | 47 | 34 | 10 | 80 (46) |
| Yttrium-90 | 11 (58) | 10 (53) | 19 | 7 | 5 | 7 | 0 | 10 (53) |
| Sorafenib | 3 (19) | 2 (13) | 16 | 1 | 2 | 10 | 3 | 8 (50) |
| No treatment | 88 (37) | 61 (26) | 238 | 24 | 28 | 54 | 132 | 39 (16) |
- Citation: Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, Poyanli A, Gulluoglu M, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol 2018; 10(1): 51-61
- URL: https://www.wjgnet.com/1948-5182/full/v10/i1/51.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i1.51